{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:38:05Z","timestamp":1792798685929,"version":"4.5.0"},"reference-count":6,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020218","name":"Chiesi USA","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/100020218","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Protalix Biotherapeutics, Inc.","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"https:\/\/ror.org\/03kr39981","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"accepted":{"date-parts":[[2024,1,15]]},"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1136\/jmg-2024-109876","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T13:20:22Z","timestamp":1712582422000},"page":"534-535","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Response to commentary: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study \u2013 determination of immunogenicity"],"prefix":"10.1136","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4112-0677","authenticated-orcid":false,"given":"David G","family":"Warnock","sequence":"first","affiliation":[{"name":"Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L","family":"Wallace","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"key":"2025101715022927000_61.6.534.1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg-2023-109818"},{"key":"2025101715022927000_61.6.534.2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg-2023-109445"},{"key":"2025101715022927000_61.6.534.3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.omtm.2022.07.009","article-title":"Pre-existing anti-drug antibodies in Fabry disease show less affinity for pegunigalsidase alfa","volume":"26","author":"Lenders","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025101715022927000_61.6.534.4","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.omtm.2022.10.007","article-title":"Antibodies against recombinant enzyme in the treatment of Fabry disease: Now you see them, now you don\u2019t","volume":"27","author":"van der Veen","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025101715022927000_61.6.534.5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2014.08.002","article-title":"Characterization of a chemically modified plant cell culture expressed human \u03b1-Galactosidase-A enzyme for treatment of Fabry disease","volume":"114","author":"Kizhner","year":"2015","journal-title":"Mol Genet Metab"},{"key":"2025101715022927000_61.6.534.6","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jimd.12080","article-title":"Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year phase 1\/2 clinical trial","volume":"42","author":"Schiffmann","year":"2019","journal-title":"J Inherit Metab Dis"}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmg-2024-109876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T22:02:37Z","timestamp":1760738557000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmg-2024-109876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":6,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,5,21]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/jmg-2024-109876"],"URL":"https:\/\/doi.org\/10.1136\/jmg-2024-109876","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"value":"0022-2593","type":"print"},{"value":"1468-6244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]}}}